Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

PHARMAKERN PORTUGAL, LDA.

NIF 507002571
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €4,773,723 67 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €4,773,723 67 contracts
A2 · Late Publication €3,204,173,868 1,501 contracts
Contract published to BASE more than 10 days after the signing date
LOW €3,204,173,868 1,501 contracts
A5 · Threshold Splitting €3,864,908 69 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €3,864,908 69 contracts
A6 · Low Competition €4,465,246 25 contracts
Only one bidder participated in a competitive procedure
MEDIUM €4,465,246 25 contracts
A9 · Price Overrun €4 1 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €4 1 contracts
A9 · Abnormal Price Reduction €3,794,480,832 715 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €3,794,480,832 715 contracts
C3 · Missing Mandatory Fields €2,108,158 38 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €2,108,158 38 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

20
€273,476,720
18
€213,926,468
33
€211,803,829
16
€208,525,828
10
€207,636,952
81
€207,107,976
31
€200,205,658
22
€193,359,958
64
€181,215,957
16
€173,317,763
6
€172,056,422
62
€165,193,406
38
€138,789,169
20
€122,290,185
66
€113,687,920
75
€103,035,139
70
€91,186,027
13
€90,170,102
125
€82,729,251
23
€76,243,379
Page 1 of 4 · 65 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 2 · 69 contracts

INFLIXIMAB 100 MG INJ / TRASTUZUMAB 420MG INJ AMP (PC.02383.2025)
PT · 11592354 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€71,500 2025-07-04
Aquisição de Anti-Psicóticos, Anestésicos e Relaxantes Musculares - AQ2022/19 SPMS
PT · 11640212 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€148,515 2025-05-08
Medicamentos
PT · 11382190 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€72,968 2025-04-17
Aquisição de Medicamentos do foro oncológico e imunomoduladores, ao abrigo do acordo quadro 2023/491, para o ano 2025
PT · 11749273 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€144,806 2025-04-10
2025001609 – Aquisição de medicamentos
PT · 11263329 · Ajuste Direto Regime G...
A5 · Threshold Splitting A6 · Low Competition
€19,040 2025-03-06
2025001678 - FAR HOSP PL - Infliximab 120 mg/ml Sol inj Caneta 1 ml SC
PT · 11250657 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,800 2025-02-16
MEDICAMENTOS
PT · 11130366 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,145 2024-12-18
Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2023/436 – Medicamentos para o Sistema Nervoso Central, 2023/437 – Medicação antialérgica, vitaminas e sais minerais e medicamentos usados no tratamento de intoxicações, 2023/491 – Medicamentos do foro oncológico e imunomodeladores, 2023/492 – Medicamentos anti-infeciosos, 2023/495 – Medicamentos do aparelho geniturinário, 2023/671 – Medicamentos diversos, 2024/780 – Medicamentos do aparelho locomotor, usados no tratamento das doenças endócrinas e hormonas e 2024/781 – Radiofármacos e dispositivos médicos radioativos, para aquisição de Medicamentos.
PT · 11452853 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€19,440 2024-12-11
Aquisição de ADALIMUMAB SC 40MG/0,4ML SOL INJ CAN para a ULSASI para o ano 2024
PT · 11049998 · Consulta Prévia
A5 · Threshold Splitting
€74,960 2024-11-18
AM/0822/2024 - Medicamento - TRASTUzumab BIOSSIMILAR 420MG FRS IV (HERZUMA) - Doentes em tratamento
PT · 10902823 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€74,100 2024-08-21
IMUNOMODULADORES - ADALIMUMAB
PT · 10875327 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction +1
€19,200 2024-08-19
241G000797/13559 - RITUXIMAB
PT · 10719090 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€73,720 2024-05-16
241G000331 - Rituximab
PT · 10601456 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€73,720 2024-03-08
VÁRIOS MEDICAMENTOS
PT · 10601496 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€72,617 2024-03-05
PA 82/PA/HPSJD/2024- Aquisição de bens para os Serviços Farmacêuticos do Hospital Prisional em 2024.
PT · 10597145 · Consulta Prévia
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€74,962 2024-02-28
Aquisição de INFLiximab BIOSSIMILAR 100 mg Pó conc sol inj Fr IV - Remsima - CPA 491/2023
PT · 10538004 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,400 2024-01-25
2023008583 - FAR HOSP PL - Infliximab 100 mg Pó sol inj Fr IV (Remsima)
PT · 10598119 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,750 2023-12-22
TRASTUZUMAB 420MG INJ AMP (PC.01038.2023)
PT · 10356054 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,296 2023-10-13
AQUISICAO DE MEDICAMENTOS PHARMAKERN PORTUGAL - Produtos Farmacêuticos, Lda.
PT · 10278978 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€146,160 2023-09-27
AQUISIÇÃO DE INFLIXIMAB 100 MG PÓ INJ (BIOSSIMILAR) REMSIMA - FARMACOVIGILÂNCIA
PT · 10642543 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€145,500 2023-08-28
TRASTUZUMAB 420MG INJ AMP
PT · 10348711 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,296 2023-08-24
Aquisição de RITUXIMAB BIO PHARMAKERN,IV,500MG INJ, ao Lab. Pharmakern, para o HFF, para o ano 2023
PT · 10216913 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,900 2023-08-22
231G001177 - RITUximab 500 mg/50 mL Sol inj Biossimil
PT · 10169762 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,460 2023-08-01
2023002924 - FAR HOSP - Infliximab 100 mg Pó sol inj Fr IV
PT · 10236336 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,940 2023-03-10
Q1/0550/2023 - Medicamentos Diversos
PT · 9813238 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€72,296 2023-02-10
AQUISIÇÃO DE MEDICAMENTOS DO APARELHO CARDIOVASCULAR: GRUPO 3
PT · 9539594 · Consulta Prévia
A5 · Threshold Splitting A2 · Late Publication +1
€19,895 2022-10-11
RITUXIMAB 500MG SOL INJ FR
PT · 9682061 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,575 2022-05-19
61/2937/2022 - Medicamento Rituximab 500 mg/50 ml Sol inj Fr 50 ml IV
PT · 9340923 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,920 2022-04-28
Aquisição de TRASTUZUMAB BIO CELTRION IV 420MG PO INJ ao Laboratório PharmaKern para o HFF para o ano 2021
PT · 9311805 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€71,250 2021-09-14
TRASTUZUMAB 150 MG PHARMAKERN
PT · 7733134 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award
€72,000 2021-06-18
Aquisição de TRASTUZUMAB BIO CELTRION IV 420MG PO INJ, ao Laboratório Pharmakern para o ano de 2021
PT · 7747642 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€71,250 2021-06-15
PC2021050101 - INFLIXIMAB
PT · 7760405 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,860 2021-05-26
Aquisição de Medicamentos
PT · 7508660 · Concurso público
A5 · Threshold Splitting A2 · Late Publication +1
€72,770 2021-01-28
1110014/2021 - MED. SN CEREBROSPINAL - EXCEPTO ANEST., R MUSC., ANALG., ANTIPIR., ANTIDEP., E ANTIPSI
PT · 7496216 · Concurso público
A5 · Threshold Splitting A2 · Late Publication +1
€72,552 2021-01-01
Conforme informação nº 146/INFO/HPSJD/2020, é necessário a aquisição de medicamentos de consumo geral e consumo hospitalar para a farmacia do hospital prisional em 2020.
PT · 7395830 · Consulta Prévia
A5 · Threshold Splitting A2 · Late Publication +1
€74,925 2020-07-13
INFLIXIMAB 100 MG (BIOSSIMILAR) REMSIMA PÓ CONC SOL INJ FR IV
PT · 6782331 · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€72,000 2020-07-09
TRASTUZUMAB 420MG INJ AMP
PT · 6659217 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€73,800 2020-05-27
Fornecimento de Rituximab ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 6546843 · Concurso público
A5 · Threshold Splitting
€149,138 2020-04-29
TRASTUZUMAB 150 MG - PHARMAKERN - ALINEA B
PT · 6734953 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€74,100 2020-04-15
Risperidona 1mg/ml Sol. Oral e Haloperidol 5mg/ml Sol. Inj.
PT · 6708811 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,950 2020-04-01
RITUXIMAB 500 MG/50 ML SOL INJ FR 50 ML IV
PT · 6534043 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€145,000 2020-02-26
Rituximab (Bios) 500 mg/50 ml sol inj fr 50 ml IV Pharmakern Extra Centralizada
PT · 6327052 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,947 2019-10-30
Rituximab (bios) 500 mg/50 ml sol inj fr 50 ml IV - Pharmakern
PT · 6327424 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,947 2019-09-14
ANTIVÍRICOS - 2º SEMESTRE
PT · 5894332 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€73,841 2019-07-17
191g002040
PT · 5641371 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,930 2019-05-21
INFLIXIMAB 100 MG (BIOSSIMILAR) PÓ CONC SOL INJ FR IV
PT · 5520379 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€148,500 2019-04-18
4180119/2019 - INFLIXIMAB 100 MG (REMSIMA) PÓ SOL INJ
PT · 5600445 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,875 2019-01-31
Diversos Medicamentos
PT · 6000356 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€148,735 2019-01-28
TRETINOINA CAPS 10 MG
PT · 7238124 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,912 2019-01-16
FI0471/2018 - INFLIXIMAB 100 MG (REMSIMA) PÓ SOL INJ
PT · 5520749 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,950 2018-09-24
Next →
Overview
Total Value Won
€3,875,306,979
Contracts Won
2,026
Score 74270 · CRITICAL RISK
NIF
507002571
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

No director data imported yet.

Director and fiscal identity data for Portuguese companies can be found in the Registo Comercial (publicacoes.mj.pt).

Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned